ATE320258T1 - Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist - Google Patents

Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist

Info

Publication number: ATE320258T1
Authority: AT; Austria
Prior art keywords: receptor antagonist; dibenzoxazepine; integrin receptor; alpha; present
Prior art date: 2000-10-24

Application number

AT01987196T

Other languages

English (en)

Inventor

Michael A Patane

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-24

Filing date

2001-10-19

Publication date

2006-04-15

2001-10-19 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE320258T1 publication Critical patent/ATE320258T1/de

Links

RVSGRNKUJJUAPV-UHFFFAOYSA-N benzo[d][1,2]benzoxazepine Chemical compound O1N=CC2=CC=CC=C2C2=CC=CC=C12 RVSGRNKUJJUAPV-UHFFFAOYSA-N 0.000 title abstract 2
108010044426 integrins Proteins 0.000 title abstract 2
102000006495 integrins Human genes 0.000 title abstract 2
239000002464 receptor antagonist Substances 0.000 title abstract 2
229940044551 receptor antagonist Drugs 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
208000006386 Bone Resorption Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
108010040765 Integrin alphaV Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
206010061289 metastatic neoplasm Diseases 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT01987196T 2000-10-24 2001-10-19 Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist ATE320258T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24282900P	2000-10-24	2000-10-24

Publications (1)

Publication Number	Publication Date
ATE320258T1 true ATE320258T1 (de)	2006-04-15

Family

ID=22916338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01987196T ATE320258T1 (de)	2000-10-24	2001-10-19	Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist

Country Status (9)

Country	Link
US (1)	US6943156B2 (de)
EP (1)	EP1331937B1 (de)
JP (1)	JP2004513953A (de)
AT (1)	ATE320258T1 (de)
AU (2)	AU3943502A (de)
CA (1)	CA2425117A1 (de)
DE (1)	DE60118025T2 (de)
ES (1)	ES2259047T3 (de)
WO (1)	WO2002040505A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1363702A4 (de) *	2001-01-30	2007-08-22	Cytopia Pty Ltd	Verfahren zur hemmung von kinasen
PL1734996T3 (pl) *	2004-04-02	2013-09-30	Univ California	Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
US20070010805A1 (en)	2005-07-08	2007-01-11	Fedewa Russell J	Method and apparatus for the treatment of tissue
CA2767409C (en)	2009-07-24	2018-10-30	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
KR101508041B1 (ko)	2012-08-10	2015-04-06	서울대학교산학협력단	디벤자제핀을 포함하는 골 대사성 질환 예방 또는 치료용 약제학적 조성물
EP3050878B1 (de)	2013-09-24	2021-10-27	FUJIFILM Corporation	Neuartige stickstoffhaltige verbindung oder salz davon oder metallkomplex davon
EP3573619A4 (de)	2017-01-27	2020-10-28	SignalRX Pharmaceuticals, Inc.	Thienopyranone und furanopyranone als kinase-, bromodomänen- und checkpoint-inhibitoren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CO4920232A1 (es) *	1997-01-08	2000-05-29	Smithkline Beecham Corp	Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
PE122699A1 (es) *	1997-09-19	2000-02-12	Smithkline Beecham Corp	Antagonistas de receptores de vitronectina
UA71586C2 (en) *	1998-12-04	2004-12-15	Smithkline Beecham Corp	A vitronectin receptor antagonist

2001
- 2001-10-19 AU AU3943502A patent/AU3943502A/xx active Pending
- 2001-10-19 CA CA002425117A patent/CA2425117A1/en not_active Abandoned
- 2001-10-19 WO PCT/US2001/045499 patent/WO2002040505A2/en not_active Ceased
- 2001-10-19 DE DE60118025T patent/DE60118025T2/de not_active Expired - Fee Related
- 2001-10-19 EP EP01987196A patent/EP1331937B1/de not_active Expired - Lifetime
- 2001-10-19 AU AU2002239435A patent/AU2002239435B2/en not_active Ceased
- 2001-10-19 US US10/415,032 patent/US6943156B2/en not_active Expired - Fee Related
- 2001-10-19 JP JP2002543513A patent/JP2004513953A/ja active Pending
- 2001-10-19 AT AT01987196T patent/ATE320258T1/de not_active IP Right Cessation
- 2001-10-19 ES ES01987196T patent/ES2259047T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1331937A4 (de)	2004-07-21
DE60118025D1 (de)	2006-05-11
ES2259047T3 (es)	2006-09-16
WO2002040505A2 (en)	2002-05-23
AU2002239435B2 (en)	2005-10-27
AU3943502A (en)	2002-05-27
JP2004513953A (ja)	2004-05-13
DE60118025T2 (de)	2006-11-23
WO2002040505A3 (en)	2002-08-08
US6943156B2 (en)	2005-09-13
US20040019035A1 (en)	2004-01-29
EP1331937B1 (de)	2006-03-15
EP1331937A2 (de)	2003-08-06
CA2425117A1 (en)	2002-05-23

Legal Events

Date	Code	Title	Description
2006-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DZ3263A1 (fr)	2000-12-07	Antagonistes du recepteur de l'alpha v integrine
TR200002557T2 (tr)	2000-12-21	İntegrin reseptörü antagonistleri
ATE236626T1 (de)	2003-04-15	Integrin antagonist
EA200000653A1 (ru)	2000-12-25	Антагонисты рецепторов интегринов
EP0901373A4 (de)	1999-07-07	Alpha v Beta 3 ANTAGONISTEN
ATE353219T1 (de)	2007-02-15	Alpha v integrin-rezeptor-antagonisten
ATE530183T1 (de)	2011-11-15	Substituierte indole und ihre verwendung als integrin-antagonisten
DE60023318D1 (de)	2006-03-02	Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
EP1594889A4 (de)	2008-03-19	Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
ATE240328T1 (de)	2003-05-15	Substituierte azaoxindolederivate
DE60038686D1 (de)	2008-06-05	Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
AU3943502A (en)	2002-05-27	Dibenzoxazepine alpha v integrin receptor antagonist
AP2000001766A0 (en)	1998-09-18	Vitronectin receptor anatagonists.
DE69911017D1 (en)	2003-10-09	Arylsulfonanilid-phosphate
ECSP003775A (es)	2001-08-27	Antagonistas del receptor integrina alfa v
NZ528853A (en)	2006-03-31	Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
ECSP992897A (es)	1999-06-01	Antagonistas del receptor de integrina
NZ506750A (en)	2003-06-30	Vitronectin receptor antagonists useful in the treatment of inflammation, cancer and cardiovascular disorders